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A B S T R A C T
Atherosclerosis is a chronic inﬂammatory disease of the arterial wall. It is characterized by
subendothelial accumulation of low-density lipoprotein cholesterol, and its subsequent modiﬁcation
at athero[12_TD$DIFF]-prone areas leads to further activation of the vascular wall and maintains vascular
inﬂammation. An entirely new level of post-transcriptional gene regulation through microRNA (miR)
expression has emerged recently as an important mechanism in the development and progression of
numerous diseases, including atherosclerosis. Recently, miR-33a/b have been shown to act as post-
transcriptional regulators of lipid metabolism, and their pharmacological inhibition diminished
atherosclerosis by raising plasma high-density lipoprotein levels. This review summarizes the current
understanding of the functions of miR-33a/b and the progress in miRNA therapeutics for treatment of
various diseases, including atherosclerosis.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Contents
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MicroRNAs (miRNAs; miRs) are endogenous, small (approxi-
mately 20–22 nucleotides in length), non-protein-coding RNAs.* [8_TD$DIFF]Correspondence to: Department of Cardiovascular Medicine, Kyoto University,
54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan. Tel.: +81 75 751 3190;
fax: +81 75 751 3203.
E-mail address: kohono@kuhp.kyoto-u.ac.jp
http://dx.doi.org/10.1016/j.jjcc.2015.10.017
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsmiRNAs bind to the 30 untranslated region (UTR) of speciﬁcmRNAs
according to the complementarity of their sequences and inhibit
translation or promote mRNA degradation. miRNAs were initially
discovered in Caenorhabditis elegans by Victor Ambros’ groupwhile
studying the gene lin-14 [1], and they were later found to be
evolutionarily conserved. More than 60% of human protein-coding
genes have been shown to be regulated by miRNAs, and so far,
approximately [13_TD$DIFF]2500 miRNAs have been identiﬁed in humans [2].
miRNAs are usually transcribed by RNA polymerase II (Pol II) in
the nucleus as longer precursors with a hairpin structure, referredreserved.
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Fig. 1.Mice have a single copy of microRNA (miR)-33, but humans have two copies
(miR-33a and miR-33b).
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processed by the Drosha (RNase III)/DGCR8 complex to form
approximately 70-nucleotide pre-mature miRNAs (Pre-miRNAs).
Pre-miRNAs are then translocated to the cytoplasm through
exportin 5, where Dicer (an miRNA-speciﬁc nuclease) cleaves
them, resulting in double-stranded miRNAs that form mature
miRNAs of 18–25 nucleotides in length. Subsequently, mature
miRNAs are incorporated into an RNA-inducing silencing complex
(RISC) by associating with Argonaute (Ago) proteins. This complex
with the miRNA targets the 30-UTR of the mRNA, which is then
responsible for the decrease in target gene expression, [15_TD$DIFF]via either
degradation of the mRNA or inhibition of protein synthesis [3].
In addition to their existence in various tissues, recent studies
have indicated that miRNAs also exist in serum, plasma, urine, and
other body ﬂuids in highly stable forms that are protected from
endogenous RNase activity by exosomes and other proteins
[4]. Circulating miRNA expression proﬁling has provided strong
molecular markers for the detection of various diseases. Altered
levels of circulating miRNAs have been observed in acute coronary
syndrome [5], heart failure, essential hypertension, and stroke.
Work over the past several years has demonstrated that
miRNAs control the expression of most of the genes associated
with high-density lipoprotein (HDL) metabolism, including the
ATP transporters, ABCA1 and ABCG1, and the scavenger receptor
SRB1 [3,6–8]. These ﬁndings suggested that miRNAs regulate HDL
biogenesis, cellular cholesterol efﬂux, and HDL cholesterol (HDL-C)
uptake in the liver, thus controlling all of the steps of reverse
cholesterol transport (RCT). Elucidation of the function of miRNAs
may provide novel strategies for the treatment of dyslipidemia. In
particular, we have intensively investigated the functions of miR-
33a/b in vivo using genetically modiﬁed mice [9–12]. The present
review summarizes the function of miR-33a/b and current
strategies for modulating the function/levels of miRNAs.
microRNA-33a/b regulates high-density lipoprotein cholesterol
in vivo
The miR-33 family consists of two intronic miRNAs, miR-33a
and miR-33b, which are encoded in the introns of SREBF2 and
SREBF1, respectively [13]. The sterol regulatory element-binding
proteins (SREBPs) are a family of membrane-bound transcription
factors that regulate fatty acid and cholesterol synthesis. SREBF1
encodes SREBP-1a and -1c, which mainly regulate lipogenic genes,
such as fatty acid synthase (FAS), stearoyl-CoA desaturase (SCD),
and acyl-CoA carboxylase 1 (ACC1). SREBF2 encodes SREBP-2,
which mainly regulates cholesterol-regulating genes, such as 3-
hydroxy-3-methylglutaryl-CoA reductase (HMGCR), and low-
density lipoprotein receptor (LDLR) [14]. In humans, miR-33a
and miR-33b are encoded in the introns of SREBF2 and SREBF1,
respectively [15], whereas in rodents there is a deletion in themiR-
33b encoding sequence and miR-33b cannot be expressed (Fig. 1).
Furthermore, miR-33a andmiR-33b share the same seed sequence
and differ in only three nucleotides. The fact thatmiR-33a andmiR-
33b are cotranscribed with their respective host genes suggests
that they regulate lipid homeostasis with their host genes.
Several groups have shown thatmiR-33a targets genes involved
in cholesterol export, such as ATP-binding cassette transporter A1
(Abca1) and Abcg1 in vivo, using either antisense technology or by
generating miR-33a-deﬁcient (knockout) mice [9,13]. ABCA1
promotes the movement of excess free cholesterol out of the cell.
In the liver, it is essential for efﬂux of cholesterol to lipid-poor
apolipoprotein A-I (apoA-I) and forms nascent HDL. In peripheral
cells, ABCA1 and ABCG1 efﬂux excess cholesterol to apoA-[16_TD$DIFF] and
HDL particles for delivery to the liver for excretion in the bile and
feces. Therefore, ABCA1 is an essential molecule for HDL biogenesis
and RCT. The ABCA1mRNA and protein half-lives are short (1–2 h),suggesting that de novo transcription and translation are important
for controlling its expression in response to stimuli. The 30-UTRs of
mouse and human ABCA1 and mouse ABCG1 contain binding sites
for miR-33a/b, and transfection of miR-33a/b strongly repressed
ABCA1 and ABCG1 mRNA and protein in a variety of cells. It was
shown that mice treated with antisense oligonucleotides or anti-
miR-33a lentivirus exhibited increased ABCA1 expression in the
liver and ABCA1 and ABCG1 expression in macrophages. Further-
more, inhibition of endogenous miR-33a in both these cell types
promotes an increase in the expression of ABCA1 and ABCG1
protein and cholesterol efﬂux to apoAI and HDL-C, indicating the
physiologically relevant role of this miRNA in regulating ABCA1
and ABCG1. Notably, in an anti-miR-33a-treated mouse model of
atherosclerosis, plasma HDL levels increased by 35–50% without
affecting other lipoproteins [13]. miR-33a knockout mice also
showed a signiﬁcant increase in the expression of ABCA1 and
ABCG1 and a 25–40% increase in serum HDL-C [9] (Fig. 2A[17_TD$DIFF]). Anti-
miR-33a therapy has been shown to contribute to enhance the RCT
pathway not only by increasing HDL-C through ABCA1 and ABCG1
upregulation but also by increasing bile secretion through
upregulation of ABCB11 and ATP8B1, which are the other targets
of miR-33a/b [16]. Using an in vivo assay to measure the efﬁciency
of RCT, it was shown that the HDL-C generated by miR-33a
inhibition was functional and increased the transport of cellular
radiolabeled cholesterol to the plasma, liver, bile acid, and feces.
Interestingly, in contrast to the results with miR-33a-deﬁcient
mice, HDL-C levels in miR-33b knock-in (KI) mice, which has miR-
33b in the same intron as in humans [12], were reduced by almost
35%, even in miR-33b KI [18_TD$DIFF]heteromice compared with the control
mice (Fig. 2B).
microRNA-33 inhibition has a beneﬁcial effect on
atherosclerosis
The function of miR-33a inhibition in animal models of
atherosclerosis has been examined by several groups. It has
already been proven that antisense inhibition of miR-33a resulted
in regression of atherosclerotic plaque in LDLR-deﬁcient mice by
promoting RCT [17]. This promotion of RCT was shown to be
achieved in two ways: by directly increasing HDL-C biogenesis in
the liver, and by increasing cellular cholesterol efﬂux from plaque
macrophages. Moreover, miR-33a-deﬁcient mice reduced the
progression of atherosclerosis in apoE-deﬁcient mice (Fig. 3)
[10]. In our study, miR-33-deﬁcient mice not only had higher and
functional HDL-C but also had macrophages with higher choles-
terol efﬂux capacity, resulting in the lower lipid accumulation in
atherosclerotic areas [10]. Other possible beneﬁcial properties of
[(Fig._2)TD$FIG]
Fig. 2. Lipid proﬁles of wild-type (WT), microRNA (miR)-33a-deﬁcient mice (knockout, KO), and miR-33b knock-in (KI) mice ( [1_TD$DIFF]cited and modiﬁed from Refs. [9,12]). (A)
Representative high-performance liquid chromatography (HPLC) analysis of serum cholesterol from male wild-type and miR-33a-deﬁcient mice. [2_TD$DIFF](B) Representative HPLC
analysis of serum cholesterol from male wild-type and miR-33b KI+/+ mice.
K. Ono / Journal of Cardiology 67 (2016) 28–3330anti-miR-33a/b therapy include an anti-inﬂammatory reaction [19_TD$DIFF]via
upregulation of ABCA1. ABCA1 decreases cell-surface cholesterol
levels, inhibits its partitioning into lipid rafts, and reduces the
responsiveness of inﬂammatory signals from innate immune
receptors. Furthermore, ABCA1 has been reported to act directly as
an anti-inﬂammatory receptor independent of its lipid transport
activities [18].
Although these preclinical studies ofmiR-33a inhibition inmice
are encouraging, it has been shown that obesity and hepatic
steatosis were observed in miR-33a-deﬁcient mice at the age of
50 weeks or when fed a high-fat diet for 12 weeks [11]. We found
that Srebf1 is a good target of miR-33a, and enhanced expression of
SREBP-1 may have caused these phenotypic changes in miR-33a-
deﬁcient mice [20_TD$DIFF] 11]. Suppression of SREBP-1 by miR-33a indicated
the existence of a more direct and ﬁne regulatory mechanism
between SREBPs. It was also shown that chronic inhibition of miR-
33a by antisense oligonucleotides increased the expression of
genes involved in fatty acid synthesis such as ACC1 and FAS in the
livers of mice [19]. It was also reported that anti-miR-33a therapy
enhanced the expression of nuclear transcription Y subunit gamma
(NFYC), a transcriptional regulator required for DNA binding and
full transcriptional activation of SREBP-responsive genes, includ-
ing ACC and FAS.[(Fig._3)TD$FIG]
Fig. 3.microRNA (miR)-33a-deﬁciency reduced atherosclerosis (cited and modiﬁed from
aorta in miR-33+/+ [3_TD$DIFF]Apoe/ and miR-33/Apoe/ male and female mice. Scale bars, 1
proximal aorta in male and female mice. Values are the means  S.E. ( [5_TD$DIFF]n = 10–11 each, *It is also of note that mice lack miR-33b, which is present in the
Srebf1 gene of medium and large mammals, and that extrapolating
the ﬁndings in rodents to humans is complicated. This difference
between mice and humans may be particularly relevant under
conditions in which the transcription of Srebf1 is upregulated, such
as feeding after fasting and hyperinsulinemia. Because such a
condition may lead to greater downregulation of cellular
cholesterol efﬂux and plasma HDL-C levels, not complete but
partial inhibition of miR-33a/b, which avoids the induction of
further Srebf1, would be beneﬁcial for the increase of HDL-C and
prevention of atherosclerosis.
Other functions of microRNA-33a/b
miR-33a/b are known to have several other target genes
including AMP-activated kinase (Ampka1) and Cpt1a, which are
involved in the regulation of lipid and glucose metabolism
[20]. However, no signiﬁcant difference in these target genes
has been observed in miR-33a-deﬁcient and miR-33b-KI mice
compared with their levels in control mice [11,12].
It has been suggested that miR-33a/b regulates stem cell self-
renewal [21_TD$DIFF]via downregulation of p53 [21]. p53 has two putativemiR-
33a/b binding sites in the 30-UTR, and miR-33s overexpressionRef. [10]). (A) Representative microscopic images of cross-sections of the proximal
mm. (B) Quantiﬁcation of the atherosclerotic plaque area in cross-sections of the
p < 0.05).
K. Ono / Journal of Cardiology 67 (2016) 28–33 31repressed p53 expression and p53-mediated apoptosis. This study
suggested that miR-33s may promote the repopulation capacity of
hematopoietic stem cells. It is known that SREBP-1 and cellular
cholesterol levels have also been shown to regulate cell-cycle
progression. Therefore, miR-33a/b may cooperate with their host
genes in regulating cell-cycle progression.
microRNA modiﬁcations and chemistry
The ability of miRNAs to regulate multiple genes in signal
transduction pathways makes them attractive therapeutic targets.
For this reason, miRNA therapeutics may be superior to other
therapies that target a single protein or use small molecules.
miRNA therapeutic approaches can be divided into two
categories: miRNA inhibition (blockade) to reduce the expression
of miRNAs upregulated in the setting of a pathological condition,
and miRNA replacement to restore the expression of miRNAs
repressed in the setting of a disease (Fig. 4).
Inhibition of microRNA function
Current strategies to inhibit miRNAs include the use of miRNA
inhibitors and miRNA sponges. An ideal miRNA inhibitor needs to
have several functions, including high afﬁnity to the target genes,
low toxicity, high speciﬁcity, resistance to exonucleases, and low
cost for synthesis.
Antisense oligonucleotides
[22_TD$DIFF]miRNA inhibitors are chemically modiﬁed single-stranded
antisense oligonucleotides[23_TD$DIFF] (ASOs) that are complimentary to the
mature miRNA. To date, angtagomiRs (target-single miRNAs
conjugated with cholesterol), antimiRs (target-single miRNAs), and
tiny antimiRs (target miRNA families) have been synthesized
(Fig. 4A). These ASOs can reduce the levels of pathogenically
expressed miRNAs. A number of chemical modiﬁcations have been
used to improve the pharmacodynamics and pharmacokinetics of
ASOs. The modiﬁcations that are most commonly used are 20-O-
methoxyethyl (20-MOE), 20-O-methyl ribose-modiﬁedRNA (20-OMe),
[(Fig._4)TD$FIG]
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Fig. 4. microRNA (miRNA) manipulation strategies. Modiﬁcation of miRNAs can be ach
expression and blue lines indicate approaches to reduce them. (A) AntagomiRs and ant
sponges for miRNA inhibition. (D) miRNA mimics for miRNA replacement.20-ﬂuoro (20-F), and locked nucleic acid (LNA)modiﬁcations. In order
to see the effect of miR-33a/b inhibition, 20-F/MOE-modiﬁed
phosphorothioate-backbone-modiﬁed antisense miR-33 was
injected into African green monkeys [22]. It was reported that
increased hepatic expression of ABCA1 and sustained increase in
plasma HDL-C levels were observed over 12 weeks. Addition of
LNAs to the ASOs increased the binding speciﬁcity. LNA-modiﬁed
oligonucleotides contain one or more nucleotides in which an
extra methylene bridge ﬁxes the ribose moiety in the 30-
[24_TD$DIFF]endoconformation [23]. This modiﬁcation possesses high afﬁnity
and results in signiﬁcant increases inmelting temperature of up to
several degrees per LNA residue and leads to the formation of a
thermodynamically strong duplex with complementary RNA. In
addition, this character of LNA oligonucleotides allows for the
generation of ‘tiny LNAs’ that bind only to the seed region of target
miRNAs. Tiny LNAs are 7–8 nucleotides long and can inhibit a
family ofmiRNAs at the same time, an advantage over antagomiRs
that can only target individual miRNAs. Rottiers et al. demon-
strated that pharmacological inhibition of the miR-33 family by a
subcutaneous delivered 8-mer LNA-modiﬁed antimiR into obese
and insulin-resistant nonhuman primates, which resulted in
derepression of miR-33 targets, such as ABCA1, and increases in
circulating HDL-C [24].
Recently, another kind of miRNA inhibitor has been developed.
These are referred to as ‘blockmirs,’ which target the miRNA-
binding site in a speciﬁc target gene (Fig. 4B) [25]. They are
designed to bind to the seed region with additional nucleotides to
increase speciﬁcity. The unique feature of blockmirs is that they
target speciﬁc mRNA while still allowing the miRNA to regulate
other target genes.
[25_TD$DIFF]miRNA sponges
A recent clinical trial indicated that ﬁve weekly injections of an
antimiR were sufﬁcient to achieve inhibition for at least 6 weeks in
humans. However, repeated injection may be necessary to allow
for longer inhibition. To overcome these barriers, ‘miRNA sponges’
were developed to inhibit miRNA activity (Fig. 4C). miRNA sponges
contain multiple miRNA[26_TD$DIFF]-binding sites, which act as competitiveanmiRs for miRNA 
miR-binding sites
ORF AAAAA(n)
C. Sponges for miRNA inhibion
ome
ORF AAAAAAAAA(n)
lockmiRs for speciﬁc target inhibion
ieved by several strategies. Red lines indicate the methods to increase target gene
imiRs for miRNA inhibition. (B) BlockmiRs for speciﬁc target inhibition. (C) miRNA
K. Ono / Journal of Cardiology 67 (2016) 28–3332inhibitors for miRNA binding. This technology mainly utilizes viral
gene transfer vectors to deliver the miRNA sponges into cells/
tissues. However, nonviral delivery systems can also be used, such
as liposomes, polysaccharides, and artiﬁcial polymers. miRNA
sponges have been used to regulate miRNAs speciﬁcally in skeletal
muscle [26].
[27_TD$DIFF]Restoration of microRNA levels
Although efforts to inhibit overexpressed miRNAs have been a
major focus over the past years, several successful strategies have
been employed to express depleted miRNAs in diseased cells/
tissues. miRNA levels are restored using oligonucleotide-based
miRNAmimics, or by the use of viruses to drive expression of a given
miRNA. miRNA mimics are double-stranded synthetic oligonucleo-
tides that are processed into a single-stranded miRNA to regulate
target genes in the cells (Fig. 4D). Montgomery et al. restored the
functional miR-29mimic to target ﬁbrotic disease [27]. The miR-29
mimicwas conjugated to cholesterol to facilitate cellular uptake and
contained mismatches to prevent it from acting as an inhibitor.
There are several reports thatmiRNAmimicswere successfully used
in clinical trials and the therapeutic potential of miRNAmimics has
been discussed [28].
Nonviral delivery
[28_TD$DIFF]Nonviral delivery of miRNAs is achieved by conjugation-based
methods, liposomes, nanoparticles, or antibody-based methods.
Lipid-conjugated dsRNAs, including palmitic acid, lauric acid, and
cholesterol, in which these lipids modiﬁed the 50-end of the sense
strand [29_TD$DIFF], have been used to facilitate cellular uptake and to add a
potent gene silencing effect for the delivery of siRNAs or miRNAs
[29]. Liposome nanoparticles have been utilized for miRNA
delivery applications. Nanoparticles can be targeted to speciﬁc
cells and tissues by adding cell [30_TD$DIFF]-surface receptor, ligands, and
antibodies [30].
[31_TD$DIFF]Viral delivery
Retrovirus, lentivirus, adeno-associated virus (AAV), and
adenovirus have been used for miRNA loss and gain of function
research. An AAV vector that delivers miRNAs driven by tissue-
speciﬁc promoters allows for speciﬁc regulation in the cell type of
choice. However, there is a concern in using these viral vectors
because of safety and efﬁcacy issues. Pre-existing immunity
against viral vectors may lead to rejection responses.
[27_TD$DIFF]Conclusion
miRNAs are able to directly regulate the expression of
transcription factors and signaling molecules and play critical
roles in numerous diseases. Given the role of miR-33a/b in
repressing cholesterol efﬂux and atheroprotective effects, pharma-
cological targeting ofmiR-33a/bmay be a promising strategy for the
treatment of atherosclerosis. Recent reports have demonstrated
the ability of exogenously administeredmiRNA inhibitors ormiRNA
mimics to modulate these pathological processes, thereby amelio-
rating disease, which opens the door for novel therapeutic
approaches in the future.
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